Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02065752 · ClinicalTrials.gov registry record · Phase 1
A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT02065752 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 2 participants.
The verdict
NCT02065752, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the bioequivalence of the fixed dose combination (two components combined in one tablet) of canagliflozin and metformin extended release (XR) tablet (dose of 2 X 50 mg/500 mg) with respect to the individual components of canagliflozin (1 x 100 mg) and metformin XR tablet (2 x 500 mg) in healthy fed participants.
Interventions
- DRUG Metformin XR, 500 mg
- DRUG Canagliflozin, 100 mg
- DRUG CANA/MET XR FDC, Formulation 1, 50 mg/500 mg
- DRUG CANA/MET XR FDC, Formulation 2, 50 mg/500 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02065752
The ClinicalTrials.gov registry entry for NCT02065752 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Metformin XR, 500 mg is the first listed.
NCT02065752 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02065752 about?
NCT02065752 is a clinical study titled "A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components". The purpose of this study is to assess the bioequivalence of the fixed dose combination (two components combined in one tablet) of canagliflozin and metformin extended release (XR) tablet (dose of 2 X 50 mg/500 mg) with respect to the individual components of canagliflozin (1 x 100 mg) and metformin...
What is the current status of trial NCT02065752?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2014-02. Estimated completion is 2014-04.
What interventions are being tested in trial NCT02065752?
The interventions under investigation include: Metformin XR, 500 mg (DRUG), Canagliflozin, 100 mg (DRUG), CANA/MET XR FDC, Formulation 1, 50 mg/500 mg (DRUG), CANA/MET XR FDC, Formulation 2, 50 mg/500 mg (DRUG).
Who is sponsoring clinical trial NCT02065752?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.